Sonoma Pharmaceu Stock Price, News & Analysis

Sonoma Pharmaceuticals (Nasdaq:SNOA) reported record quarterly revenue of $5.6M for Q2 fiscal 2026, a 57% increase year‑over‑year, and six‑month revenue of $9.6M, up 38% YoY. U.S. revenue rose 115% for the quarter and 86% for the six months. Gross profit was $2.1M (38% margin) for the quarter and $3.6M (37% margin) for six months. Net loss was $0.5M for the quarter and $1.8M for six months; the company reported improvements in EBITDA (quarterly EBITDA loss $0.2M, six‑month EBITDA loss $0.8M). Cash and cash equivalents were $3.0M as of September 30, 2025.

Recent commercial and regulatory milestones include Walmart rollout of diaper rash products (Aug 13, 2025), NPF seal for Reliefacyn (Aug 26, 2025), MoCRA listing and facility registration (Oct 7, 2025), and a Medline wound cleanser launch (Oct 14, 2025).

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the launch of a new HOCl wound cleanser manufactured by Sonoma for Medline Industries, LP, on October 14, 2025.

The product will be distributed by Medline into U.S. hospital systems, home healthcare and other healthcare channels. The collaboration between Sonoma and Medline began in 2024 and pairs Sonoma's Microcyn technology with Medline's nationwide distribution to provide clinicians an advanced wound-cleansing option that aims to promote healing and reduce infection risk without harming healthy tissue.

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced on October 7, 2025 that it has registered its manufacturing facility and listed a Microcyn-based facial spray under the FDA's Modernization of Cosmetics Regulation Act (MoCRA). The MoCRA registration enables Sonoma to manufacture and commercialize Microcyn technology products as cosmetics in the U.S., expanding the company's regulatory footprint beyond its existing FDA medical device establishment registration and 510(k)-cleared portfolio.

The company said this step increases access to U.S. cosmetics and dermatology consumer markets, citing a projected U.S. skin care market near $40 billion by 2030, and positions Sonoma to pursue growth with its patented hypochlorous acid technology.

Sonoma Pharmaceuticals (Nasdaq:SNOA), a healthcare company specializing in Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in the upcoming Lytham Partners Fall 2025 Investor Conference.

The virtual event will take place on September 30, 2025, featuring a webcast presentation at 2:00 p.m. ET. Management will also be available for one-on-one meetings with investors throughout the conference. The company develops products for various applications including wound care, eye care, dermatological conditions, podiatry, and animal health care.

Sonoma Pharmaceuticals (Nasdaq:SNOA), a healthcare company specializing in Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has received the National Psoriasis Foundation (NPF) Seal of Recognition for its Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel.

The product, which previously earned the National Eczema Association Seal of Acceptance, was independently reviewed by medical experts and met NPF's standards for safety, ingredient quality, and tolerability on sensitive skin. This recognition validates the product's efficacy for people with chronic skin conditions including psoriasis, eczema, and sensitive skin.

Sonoma Pharmaceuticals (Nasdaq:SNOA) has announced the launch of its HOCl-based diaper rash product in major U.S. retail channels. The antimicrobial hydrogel, based on their patented Microcyn® technology, is now available in 3,600 Walmart stores, Amazon.com, and various large grocery chains.

This launch marks Sonoma's strategic expansion into the over-the-counter consumer market, offering their stabilized hypochlorous acid (HOCl) technology directly to consumers seeking solutions for diaper rash and skin irritations. The product is being distributed through their U.S.-based distribution partner.

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported its Q1 FY2026 financial results, showing significant growth with total revenue reaching $4.0 million, an 18% increase year-over-year. The company demonstrated strong performance in key markets, with U.S. revenue surging 57% and European revenue growing 14%.

Notable achievements include expanded partnerships with major U.S. retailers, launch of acne products in 1,200+ U.K. stores, and new regulatory approval in Ukraine. Despite revenue growth, the company reported a net loss of $1.2 million and held cash reserves of $3.6 million as of June 30, 2025. Gross profit margin slightly decreased to 36% from 39% in the previous year.

Sonoma Pharmaceuticals (NASDAQ:SNOA) reported strong financial results for FY2025 and Q4 2025, showing significant improvements across key metrics. Q4 revenue increased 9% to $3.8M, while FY2025 revenue grew 12% to $14.3M. The company reduced its net loss by 27% in Q4 and 29% for the full year. EBITDA loss improved substantially, down 59% in Q4 and 17% for FY2025. Gross profit margins improved to 41% in Q4 2025 from 32% in Q4 2024. Notable achievements include early compliance with EU Medical Device Regulation, MHRA registration in the UK, and expanded distribution networks. The company launched acne products in 1,200+ UK stores and received regulatory approval in Ukraine. Operating expenses decreased by 13% in Q4 and 3% for the full year, reflecting successful cost containment efforts. As of March 31, 2025, cash position stood at $5.4M.

Sonoma Pharmaceuticals (NASDAQ:SNOA) has announced the successful registration of its hypochlorous acid-based acne products with the UK's Medicines & Healthcare products Regulatory Agency (MHRA). The company will launch its products through a major UK pharmacy chain, reaching over 1,200 stores nationwide.

The product line features an acne toner and balancing serum, which will be marketed under the retailer's private label brand. These products are based on Sonoma's patented Microcyn technology, utilizing stabilized hypochlorous acid (HOCl). The formulation offers a natural alternative to traditional acne treatments containing alcohol and benzoyl peroxide.